Cancer research made in Tuebingen
iFIT Cluster of Excellence

Zurück zum Hauptmenü
Zum Menü der Einrichtung

312

Address: Geschäftsstelle
Röntgenweg 11
72076 Tübingen

frontend.sr-only_#{element.icon}: +49 (0)7071-29 83625

frontend.sr-only_#{element.icon}: ifitoffice@med.uni-tuebingen.de

Publications

Here you will find all relevant publications that are directly related to the iFIT Cluster of Excellence and have an impact factor > 10, sorted by year.

2019

  • Rammensee, HG., Wiesmüller, KH., Chandran, P.A. et al. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. j. immunotherapy cancer 7, 307 (2019). https://doi.org/10.1186/s40425-019-0796-5
  • Paczulla, A.M., Rothfelder, K., Raffel, S. et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature 572, 254–259 (2019). https://doi.org/10.1038/s41586-019-1410-1
  • Hilf, N., Kuttruff-Coqui, S., Frenzel, K. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240–245 (2019). https://doi.org/10.1038/s41586-018-0810-y
  • Weiss J, Ruff C, Grosse U, Grözinger G, Horger M, Nikolaou K, Gatidis S. Assessment of Hepatic Perfusion Using GRASP MRI: Bringing Liver MRI on a New Level. Invest Radiol. 2019 Dec;54(12):737-743. 10.1097/RLI.0000000000000586.
  • Dimitrov S, Lange T, Gouttefangeas C, Jensen ATR, Szczepanski M, Lehnnolz J, Soekadar S, Rammensee HG, Born J, Besedovsky L. Gαs-coupled receptor signaling and sleep regulate integrin activation of human antigen-specific T cells. J Exp Med. 2019 Mar 4;216(3):517-526. 10.1084/jem.20181169.
  • Zelba H, Bedke J, Hennenlotter J, Mostböck S, Zettl M, Zichner T, Chandran A, Stenzl A, Rammensee HG, Gouttefangeas C. PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma. Cancer Immunol Res. 2019 Nov;7(11):1891-1899. 10.1158/2326-6066.CIR-19-0146.
  • Moya IM, Castaldo SA, Van den Mooter L, Soheily S, Sansores-Garcia L, Jacobs J, Mannaerts I, Xie J, Verboven E, Hillen H, Algueró-Nadal A, Karaman R, Van Haele M, Kowalczyk W, De Waegeneer M, Verhulst S, Karras P, van Huffel L, Zender L, Marine JC, Roskams T, Johnson R, Aerts S, van Grunsven LA, Halder G. Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. Science. 2019 Nov 22;366(6468):1029-1034. 10.1126/science.aaw9886.
  • Mannheim JG, Mamach M, Reder S, Traxl A, Mucha N, Disselhorst JA, Mittelhäuser M, Kuntner C, Thackeray JT, Ziegler S, Wanek T, Bankstahl JP, Pichler BJ. Reproducibility and Comparability of Preclinical PET Imaging Data: A Multicenter Small-Animal PET Study. J Nucl Med. 2019 Oct;60(10):1483-1491. 10.2967/jnumed.118.221994.
  • Brauch H, Schroth W, Mürdter T, Schwab M. Tamoxifen Pharmacogenetics and Metabolism: The Same Is Not the Same. J Clin Oncol. 2019 Aug 1;37(22):1981-1982. 10.1200/JCO.19.00507
  • Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood. 2019 Feb 7;133(6):550-565. 10.1182/blood-2018-07-866830.
  • Hoffmann SHL, Reck DI, Maurer A, Fehrenbacher B, Sceneay JE, Poxleitner M, Öz HH, Ehrlichmann W, Reischl G, Fuchs K, Schaller M, Hartl D, Kneilling M, Möller A, Pichler BJ, Griessinger CM. Visualization and quantification of in vivo homing kinetics of myeloid-derived suppressor cells in primary and metastatic cancer. Theranostics. 2019 Aug 12;9(20):5869-5885. 10.7150/thno.33275.  

2020

  • Escala-Garcia, M., Abraham, J., Andrulis, I.L. et al. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nat Commun 11, 312 (2020). https://doi.org/10.1038/s41467-019-14100-6
  • Brenner E, Schörg BF, Ahmetlić F, Wieder T, Hilke FJ, Simon N, Schroeder C, Demidov G, Riedel T, Fehrenbacher B, Schaller M, Forschner A, Eigentler T, Niessner H, Sinnberg T, Böhm KS, Hömberg N, Braumüller H, Dauch D, Zwirner S, Zender L, Sonanini D, Geishauser A, Bauer J, Eichner M, Jarick KJ, Beilhack A, Biskup S, Döcker D, Schadendorf D, Quintanilla-Martinez L, Pichler BJ, Kneilling M, Mocikat R, Röcken M. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun. 2020 Mar 12;11(1):1335. 10.1038/s41467-020-14987-6.
  • Schwenck J, Schörg B, Fiz F, Sonanini D, Forschner A, Eigentler T, Weide B, Martella M, Gonzalez-Menendez I, Campi C, Sambuceti G, Seith F, Quintanilla-Martinez L, Garbe C, Pfannenberg C, Röcken M, la Fougere C, Pichler BJ, Kneilling M. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo18F-FDG-PET. Theranostics. 2020 Jan 1;10(2):925-937. 10.7150/thno.35989.
  • Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindström S, Behrens S, Michailidou K, Dennis J, Bolla MK, Wang Q, Jung A, Abu-Ful Z, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Freeman LEB, Becher H, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bernstein L, Bojesen SE, Brauch H, Brenner H, Brüning T, Cai Q, Campa D, Canzian F, Carracedo A, Carter BD, Castelao JE, Chanock SJ, Chatterjee N, Chenevix-Trench G, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Dai JY, Earp HS, Ekici AB, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fritschi L, Gabrielson M, Gago-Dominguez M, Gao C, Gapstur SM, Gaudet MM, Giles GG, González-Neira A, Guénel P, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Hatse S, Heyworth J, Holleczek B, Hoover RN, Hopper JL, Howell A, Hunter DJ; ABCTB Investigators; kConFab/AOCS Investigators; John EM, Jones ME, Kaaks R, Keeman R, Kitahara CM, Ko YD, Koutros S, Kurian AW, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Linet M, Lissowska J, Llaneza A, MacInnis RJ, Martinez ME, Maurer T, McLean C, Neuhausen SL, Newman WG, Norman A, O'Brien KM, Olshan AF, Olson JE, Olsson H, Orr N, Perou CM, Pita G, Polley EC, Prentice RL, Rennert G, Rennert HS, Ruddy KJ, Sandler DP, Saunders C, Schoemaker MJ, Schöttker B, Schumacher F, Scott C, Scott RJ, Shu XO, Smeets A, Southey MC, Spinelli JJ, Stone J, Swerdlow AJ, Tamimi RM, Taylor JA, Troester MA, Vachon CM, van Veen EM, Wang X, Weinberg CR, Weltens C, Willett W, Winham SJ, Wolk A, Yang XR, Zheng W, Ziogas A, Dunning AM, Pharoah PDP, Schmidt MK, Kraft P, Easton DF, Milne RL, García-Closas M, Chang-Claude J. Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. J Natl Cancer Inst. 2021 Mar 1;113(3):329-337. 10.1093/jnci/djaa056.
  • Fachal, L., Aschard, H., Beesley, J. et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet 52, 56–73 (2020). https://doi.org/10.1038/s41588-019-0537-1
  • Zhang, H., Ahearn, T.U., Lecarpentier, J. et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet 52, 572–581 (2020). https://doi.org/10.1038/s41588-020-0609-2
  • Schroth W, Büttner FA, Kandabarau S, Hoppe R, Fritz P, Kumbrink J, Kirchner T, Brauer HA, Ren Y, Henderson D, Madden SF, Sauer G, Fehm T, Wallwiener D, Fasching PA, Mürdter T, Schwab M, Brauch H; German Tamoxifen and AI Clinicians Group. Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients. Clin Cancer Res. 2020 Dec 15;26(24):6523-6534. 10.1158/1078-0432.CCR-20-1923.
  • Behling F, Fodi C, Gepfner-Tuma I, Kaltenbach K, Renovanz M, Paulsen F, Skardelly M, Honegger J, Tatagiba M; International Consortium on Meningiomas; Schittenhelm J, Tabatabai G. H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort. Neuro Oncol. 2021 Aug 2;23(8):1273-1281. 10.1093/neuonc/noaa303.
  • Wang J, Jelcic I, Mühlenbruch L, Haunerdinger V, Toussaint NC, Zhao Y, Cruciani C, Faigle W, Naghavian R, Foege M, Binder TMC, Eiermann T, Opitz L, Fuentes-Font L, Reynolds R, Kwok WW, Nguyen JT, Lee JH, Lutterotti A, Münz C, Rammensee HG, Hauri-Hohl M, Sospedra M, Stevanovic S, Martin R. HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. Cell. 2020 Nov 25;183(5):1264-1281.e20. 10.1016/j.cell.2020.09.054.
  • Lübke M, Spalt S, Kowalewski DJ, Zimmermann C, Bauersfeld L, Nelde A, Bichmann L, Marcu A, Peper JK, Kohlbacher O, Walz JS, Le-Trilling VTK, Hengel H, Rammensee HG, Stevanović S, Halenius A. Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models. J Exp Med. 2020 Mar 2;217(3):jem.20191164. 10.1084/jem.20191164.
  • Schmidt-Hegemann NS, Kroeze SGC, Henkenberens C, Vogel MME, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Eiber M, Mix M, la Fougère C, Müller AC, Grosu AL, Combs SE, Christiansen H, Guckenberger M, Belka C. Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1852-1863. 10.1007/s00259-020-04708-y.
  • Seith F, Forschner A, Weide B, Gückel B, Schwartz M, Schwenck J, Othman AE, Fenchel M, Garbe C, Nikolaou K, Schwenzer N, la Fougère C, Pfannenberg C. Is there a link between very early changes of primary and secondary lymphoid organs in 18F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy? J Immunother Cancer. 2020 Aug;8(2):e000656. 10.1136/jitc-2020-000656.
  • Zbinden A, Layland SL, Urbanczyk M, Carvajal Berrio DA, Marzi J, Zauner M, Hammerschmidt A, Brauchle EM, Sudrow K, Fink S, Templin M, Liebscher S, Klein G, Deb A, Duffy GP, Crooks GM, Eble JA, Mikkola HKA, Nsair A, Seifert M, Schenke-Layland K. Nidogen-1 Mitigates Ischemia and Promotes Tissue Survival and Regeneration. Adv Sci (Weinh). 2020 Dec 21;8(4):2002500. 10.1002/advs.202002500.
  • Bresnahan E, Ramadori P, Heikenwalder M, Zender L, Lujambio A. Novel patient-derived preclinical models of liver cancer. J Hepatol. 2020 Feb;72(2):239-249. 10.1016/j.jhep.2019.09.028.
  • Michelotti FC, Bowden G, Küppers A, Joosten L, Maczewsky J, Nischwitz V, Drews G, Maurer A, Gotthardt M, Schmid AM, Pichler BJ. PET/MRI enables simultaneous in vivo quantification of β-cell mass and function. Theranostics. 2020 Jan 1;10(1):398-410. 10.7150/thno.33410.
  • Vogel MME, Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Mix M, la Fougère C, Eiber M, Christiansen H, Belka C, Grosu AL, Müller AC, Guckenberger M, Combs SE. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2328-2338. 10.1007/s00259-020-04760-8.
  • Grimm J, Kiessling F, Pichler BJ. Quo Vadis, Molecular Imaging? J Nucl Med. 2020 Oct;61(10):1428-1434. 10.2967/jnumed.120.241984.
  • Nelde, A., Bilich, T., Heitmann, J.S. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol 22, 74–85 (2021). https://doi.org/10.1038/s41590-020-00808-x
  • Bucher P, Erdmann T, Grondona P, Xu W, Schmitt A, Schürch C, Zapukhlyak M, Schönfeld C, Serfling E, Kramer D, Grau M, Klener P, Lengerke C, Schulze-Osthoff K, Lenz G, Hailfinger S. Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma. Blood. 2020 Jan 9;135(2):121-132. 10.1182/blood.2019001866.
  • Spenlé C, Loustau T, Murdamoothoo D, Erne W, Beghelli-de la Forest Divonne S, Veber R, Petti L, Bourdely P, Mörgelin M, Brauchle EM, Cremel G, Randrianarisoa V, Camara A, Rekima S, Schaub S, Nouhen K, Imhof T, Hansen U, Paul N, Carapito R, Pythoud N, Hirschler A, Carapito C, Dumortier H, Mueller CG, Koch M, Schenke-Layland K, Kon S, Sudaka A, Anjuère F, Van Obberghen-Schilling E, Orend G. Tenascin-C Orchestrates an Immune-Suppressive Tumor Microenvironment in Oral Squamous Cell Carcinoma. Cancer Immunol Res. 2020 Sep;8(9):1122-1138. 10.1158/2326-6066.CIR-20-0074.
  • Müller A, Dickmanns A, Resch C, Schäkel K, Hailfinger S, Dobbelstein M, Schulze-Osthoff K, Kramer D. The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis. J Clin Invest. 2020 Nov 2;130(11):5765-5781. 10.1172/JCI134217.
  • Ewels, P.A., Peltzer, A., Fillinger, S. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol 38, 276–278 (2020). https://doi.org/10.1038/s41587-020-0439-x
  • Franke M, Bieber M, Kraft P, Weber ANR, Stoll G, Schuhmann MK. The NLRP3 inflammasome drives inflammation in ischemia/reperfusion injury after transient middle cerebral artery occlusion in mice. Brain Behav Immun. 2021 Feb;92:223-233. 10.1016/j.bbi.2020.12.009.
  • Urbanczyk M, Layland SL, Schenke-Layland K. The role of extracellular matrix in biomechanics and its impact on bioengineering of cells and 3D tissues. Matrix Biol. 2020 Jan;85-86:1-14. 10.1016/j.matbio.2019.11.005.
  • Wolter, K., Zender, L. Therapy-induced senescence — an induced synthetic lethality in liver cancer?. Nat Rev Gastroenterol Hepatol 17, 135–136 (2020). https://doi.org/10.1038/s41575-020-0262-3
  • Kauer J, Hörner S, Osburg L, Müller S, Märklin M, Heitmann JS, Zekri L, Rammensee HG, Salih HR, Jung G. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. J Immunother Cancer. 2020 May;8(1):e000621. 10.1136/jitc-2020-000621.
  • Haen, S.P., Löffler, M.W., Rammensee, HG. et al. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev Clin Oncol 17, 595–610 (2020). https://doi.org/10.1038/s41571-020-0387-x 
  • Schuhmacher J, Heidu S, Balchen T, Richardson JR, Schmeltz C, Sonne J, Schweiker J, Rammensee HG, Thor Straten P, Røder MA, Brasso K, Gouttefangeas C. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. J Immunother Cancer. 2020 Nov;8(2):e001157. 10.1136/jitc-2020-001157. 
  • Reustle, A., Moreno Di, M., Meyerhoff, C. et al. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Med 12, 32 (2020).  10.1186/s13073-020-00731-8
  • Schroth, W., Büttner F. A., Kandabarau S. et al. Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor–Positive Breast Cancer Patients. Clin Cancer Res 26, 24 (2020). https://doi.org/10.1158/1078-0432.CCR-20-1923
  • Seith, F., Forschner, A., Weide B. et al. Is there a link between very early changes of primary and secondary lymphoid organs in 18F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy? J Immunother Cancer 8, 2 (2020). 10.1136/jitc-2020-000656
  • Spenlé, C., Loustau, T., Murdamoothoo, D. et. al. Tenascin-C Orchestrates an Immune-Suppressive Tumor Microenvironment in Oral Squamous Cell Carcinoma. Cancer Immunol Res 8, 9 (2020). https://doi.org/10.1158/2326-6066.CIR-20-0074
  • Schwenck, J., Schörg, B., Fiz, F. et al. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo 18F-FDG-PET. Theranostics 10, 2 (2020). 10.7150/thno.35989


2021

  • Coignard, J., Lush, M., Beesley, J. et al. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun 12, 1078 (2021). https://doi.org/10.1038/s41467-020-20496-3.
  • Heitmann, J.S., Bilich, T., Tandler, C. et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature 601, 617–622 (2022). https://doi.org/10.1038/s41586-021-04232-5
  • Brendlin AS, Peisen F, Almansour H, Afat S, Eigentler T, Amaral T, Faby S, Calvarons AF, Nikolaou K, Othman AE. A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma. J Immunother Cancer. 2021 Nov;9(11):e003261. 10.1136/jitc-2021-003261.
  • Anbu S, Hoffmann SHL, Carniato F, Kenning L, Price TW, Prior TJ, Botta M, Martins AF, Stasiuk GJ. A Single-Pot Template Reaction Towards a Manganese-Based T1 Contrast Agent. Angew Chem Int Ed Engl. 2021 May 3;60(19):10736-10744. 10.1002/anie.202100885.
  • Zekri L, Vogt F, Osburg L, Müller S, Kauer J, Manz T, Pflügler M, Maurer A, Heitmann JS, Hagelstein I, Märklin M, Hörner S, Todenhöfer T, Calaminus C, Stenzl A, Pichler B, la Fougère C, Schneider MA, Rammensee HG, Zender L, Sipos B, Salih HR, Jung G. An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer. EMBO Mol Med. 2021 Feb 5;13(2):e11902. 10.15252/emmm.201911902.
  • Brandhorst D, Brandhorst H, Lee Layland S, Acreman S, Schenke-Layland K, Johnson PRV. Basement membrane proteins improve human islet survival in hypoxia: Implications for islet inflammation. Acta Biomater. 2022 Jan 1;137:92-102. 10.1016/j.actbio.2021.10.013.      
  • Dorling L, ... Bogdanova NV, ... Bremer M, ...Christiansen H, ... Dörk T, ... Hillemanns P, ... Park-Simon TW, ... Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021; 384(5):428-439. 10.1056/NEJMoa1913948.
  • Weigelin, B., den Boer, A.T., Wagena, E. et al. Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity. Nat Commun 12, 5217 (2021). https://doi.org/10.1038/s41467-021-25282-3
  • Stadelmann K, Weghofer A, Urbanczyk M, Maulana TI, Loskill P, Jones PD, Schenke-Layland K. Development of a bi-layered cryogenic electrospun polylactic acid scaffold to study calcific aortic valve disease in a 3D co-culture model. Acta Biomater. 2022 Mar 1;140:364-378. 10.1016/j.actbio.2021.11.030.
  • Bonito V, Koch SE, Krebber MM, Carvajal-Berrio DA, Marzi J, Duijvelshoff R, Lurier EB, Buscone S, Dekker S, de Jong SMJ, Mes T, Vaessen KRD, Brauchle EM, Bosman AW, Schenke-Layland K, Verhaar MC, Dankers PYW, Smits AIPM, Bouten CVC. Distinct Effects of Heparin and Interleukin-4 Functionalization on Macrophage Polarization and In Situ Arterial Tissue Regeneration Using Resorbable Supramolecular Vascular Grafts in Rats. Adv Healthc Mater. 2021 Nov;10(21):e2101103. 10.1002/adhm.202101103.
  • Bochem J, Zelba H, Spreuer J, Amaral T, Wagner NB, Gaissler A, Pop OT, Thiel K, Yurttas C, Soffel D, Forchhammer S, Sinnberg T, Niessner H, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler TK, Löffler MW, Weide B, Wistuba-Hamprecht K. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. J Immunother Cancer. 2021 Dec;9(12):e003439. 10.1136/jitc-2021-003439.
  • Becker, M., Strengert, M., Junker, D. et al. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Nat Commun 12, 1152 (2021). https://doi.org/10.1038/s41467-021-20973-3.
  • Stanulla, M., Schaeffeler, E., Möricke, A. et al. Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. Leukemia 35, 2650–2657 (2021). https://doi.org/10.1038/s41375-021-01203-7.
  • Marcu A, Bichmann L, Kuchenbecker L, Kowalewski DJ, Freudenmann LK, Backert L, Mühlenbruch L, Szolek A, Lübke M, Wagner P, Engler T, Matovina S, Wang J, Hauri-Hohl M, Martin R, Kapolou K, Walz JS, Velz J, Moch H, Regli L, Silginer M, Weller M, Löffler MW, Erhard F, Schlosser A, Kohlbacher O, Stevanović S, Rammensee HG, Neidert MC. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. J Immunother Cancer. 2021 Apr;9(4):e002071. 10.1136/jitc-2020-002071.
  • Drakhlis, L., Biswanath, S., Farr, CM. et al. Human heart-forming organoids recapitulate early heart and foregut development. Nat Biotechnol 39, 737–746 (2021). https://doi.org/10.1038/s41587-021-00815-9.
  • Becker, M., Dulovic, A., Junker, D. et al. Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. Nat Commun 12, 3109 (2021). https://doi.org/10.1038/s41467-021-23473-6.
  • Mehling R, Schwenck J, Lemberg C, Trautwein C, Zizmare L, Kramer D, Müller A, Fehrenbacher B, Gonzalez-Menendez I, Quintanilla-Martinez L, Schröder K, Brandes RP, Schaller M, Ruf W, Eichner M, Ghoreschi K, Röcken M, Pichler BJ, Kneilling M. Immunomodulatory role of reactive oxygen species and nitrogen species during T cell-driven neutrophil-enriched acute and chronic cutaneous delayed-type hypersensitivity reactions. Theranostics. 2021 Jan 1;11(2):470-490. 10.7150/thno.51462.
  • De Kort BJ, Marzi J, Brauchle EM, Lichauco AM, Bauer HS, Serrero A, Dekker S, Cox MAJ, Schoen FJ, Schenke-Layland K, Bouten CVC, Smits AIPM. Inflammatory and regenerative processes in bioresorbable synthetic pulmonary valves up to two years in sheep-Spatiotemporal insights augmented by Raman microspectroscopy. Acta Biomater. 2021 Nov;135:243-259. 10.1016/j.actbio.2021.09.005.
  • Petrigliano, F.A., Liu, N.Q., Lee, S. et al. Long-term repair of porcine articular cartilage using cryopreservable, clinically compatible human embryonic stem cell-derived chondrocytes. npj Regen Med 6, 77 (2021). https://doi.org/10.1038/s41536-021-00187-3.
  • Sonanini D, Griessinger CM, Schörg BF, Knopf P, Dittmann K, Röcken M, Pichler BJ, Kneilling M. Low-dose total body irradiation facilitates antitumoral Th1 immune responses. Theranostics. 2021 Jun 16;11(16):7700-7714. 10.7150/thno.61459.
  • Rudalska, R., Harbig, J., Snaebjornsson, M.T. et al. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat Cancer 2, 201–217 (2021). https://doi.org/10.1038/s43018-020-00168-3.
  • Castaneda-Vega S, Katiyar P, Russo F, Patzwaldt K, Schnabel L, Mathes S, Hempel JM, Kohlhofer U, Gonzalez-Menendez I, Quintanilla-Martinez L, Ziemann U, la Fougere C, Ernemann U, Pichler BJ, Disselhorst JA, Poli S. Machine learning identifies stroke features between species. Theranostics. 2021 Jan 1;11(6):3017-3034. 10.7150/thno.51887.
  • Slaats J, Dieteren CE, Wagena E, Wolf L, Raaijmakers TK, van der Laak JA, Figdor CG, Weigelin B, Friedl P. Metabolic Screening of Cytotoxic T-cell Effector Function Reveals the Role of CRAC Channels in Regulating Lethal Hit Delivery. Cancer Immunol Res. 2021 Aug;9(8):926-938. https://pubmed.ncbi.nlm.nih.gov/34226201/.
  • Pfister, D., Núñez, N.G., Pinyol, R. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450–456 (2021). https://doi.org/10.1038/s41586-021-03362-0.
  • Saad H, Aziz S, Gehringer M, Kramer M, Straetener J, Berscheid A, Brötz-Oesterhelt H, Gross H. Nocathioamides, Uncovered by a Tunable Metabologenomic Approach, Define a Novel Class of Chimeric Lanthipeptides. Angew Chem Int Ed Engl. 2021 Jul 19;60(30):16472-16479. 10.1002/anie.202102571.
  • Hinterleitner, C., Strähle, J., Malenke, E. et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun 12, 7005 (2021). https://doi.org/10.1038/s41467-021-27303-7
  • Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar ML, Peter A, Hörber S, Bauer J, Rieth J, Wacker M, Berner F, Flatz L, Held S, Brossart P, Märklin M, Wagner P, Erne E, Klein R, Rammensee HG, Salih HR, Walz JS. Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. Cancer Discov. 2021 Aug;11(8):1982-1995. 10.1158/2159-8290.CD-21-0191.
  • Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, Chin L, Filliol A, Wen W, Song X, Decker A, Worley J, Caviglia JM, Yu L, Yin D, Saito Y, Savage T, Wells RG, Mack M, Zender L, Arpaia N, Remotti HE, Rabadan R, Sims P, Leblond AL, Weber A, Riener MO, Stockwell BR, Gaublomme J, Llovet JM, Kalluri R, Michalopoulos GK, Seki E, Sia D, Chen X, Califano A, Schwabe RF. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell. 2021 Jun 14;39(6):866-882.e11. 10.1016/j.ccell.2021.03.012.
  • Sugiyama K, Marzi J, Alber J, Brauchle EM, Ando M, Yamashiro Y, Ramkhelawon B, Schenke-Layland K, Yanagisawa H. Raman microspectroscopy and Raman imaging reveal biomarkers specific for thoracic aortic aneurysms. Cell Rep Med. 2021 Apr 28;2(5):100261. 10.1016/j.xcrm.2021.100261.
  • Nelde, A., Bilich, T., Heitmann, J.S. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol 22, 74–85 (2021). https://doi.org/10.1038/s41590-020-00808-x.
  • Heinrich B, Brown ZJ, Diggs LP, Vormehr M, Ma C, Subramanyam V, Rosato U, Ruf B, Walz JS, McVey JC, Wabitsch S, Fu Q, Yu SJ, Zhang Q, Lai CW, Sahin U, Greten TF. Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology. 2021 Jan;160(1):331-345.e6. 10.1053/j.gastro.2020.09.031.
  • Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Rachfalski D, Märklin M, Stevanović S, Rammensee HG, Salih HR, Walz JS. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Sci Transl Med. 2021 Apr 21;13(590):eabf7517. 10.1126/scitranslmed.abf7517.
  • Huang KM, Zavorka Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proc Natl Acad Sci U S A. 2021 Feb 2;118(5):e2020168118. 10.1073/pnas.2020168118.
  • Nording, H., Baron, L., Haberthür, D. et al. The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets. Nat Commun 12, 3352 (2021). https://doi.org/10.1038/s41467-021-23499-w.
  • Li, X., Ramadori, P., Pfister, D. et al. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer 21, 541–557 (2021). https://doi.org/10.1038/s41568-021-00383-9.
  • Filali-Mouncef Y, Hunter C, Roccio F, Zagkou S, Dupont N, Primard C, Proikas-Cezanne T, Reggiori F. The ménage à trois of autophagy, lipid droplets and liver disease. Autophagy. 2022 Jan;18(1):50-72. 10.1080/15548627.2021.1895658.
  • van Tilburg CM, Pfaff E, Pajtler KW, Langenberg KPS, Fiesel P, Jones BC, Balasubramanian GP, Stark S, Johann PD, Blattner-Johnson M, Schramm K, Dikow N, Hirsch S, Sutter C, Grund K, von Stackelberg A, Kulozik AE, Lissat A, Borkhardt A, Meisel R, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, von Schweinitz D, Schmid I, Kramm CM, von Bueren AO, Calaminus G, Vorwerk P, Graf N, Westermann F, Fischer M, Eggert A, Burkhardt B, Wößmann W, Nathrath M, Hecker-Nolting S, Frühwald MC, Schneider DT, Brecht IB, Ketteler P, Fulda S, Koscielniak E, Meister MT, Scheer M, Hettmer S, Schwab M, Tremmel R, Øra I, Hutter C, Gerber NU, Lohi O, Kazanowska B, Kattamis A, Filippidou M, Goemans B, Zwaan CM, Milde T, Jäger N, Wolf S, Reuss D, Sahm F, von Deimling A, Dirksen U, Freitag A, Witt R, Lichter P, Kopp-Schneider A, Jones DTW, Molenaar JJ, Capper D, Pfister SM, Witt O. The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discov. 2021 Nov;11(11):2764-2779. 10.1158/2159-8290.CD-21-0094.
  • Dittmann H, Kaltenbach S, Weissinger M, Fiz F, Martus P, Pritzkow M, Kupferschlaeger J, la Fougère C. The Prognostic Value of Quantitative Bone SPECT/CT Before 223Ra Treatment in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2021 Jan;62(1):48-54. 10.2967/jnumed.119.240408.
  • Stotz S, Kinzler J, Nies AT, Schwab M, Maurer A. Two experts and a newbie: [18F]PARPi vs [18F]FTT vs [18F]FPyPARP-a comparison of PARP imaging agents. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):834-846. 10.1007/s00259-021-05436-7.         
  • Bilich, T., Roerden, M., Maringer Y. et. al. Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. Cancer Discov 11, 8 (2021). https://doi.org/10.1158/2159-8290.CD-21-0191
  • Heinrich, B., Brown Z. J., Diggs, L.P. et. al. Steatohepatitis Impairs T-cell–Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology 160, 1 (2021). https://doi.org/10.1053/j.gastro.2020.09.031
  • Nelde, A., Bilich, T., Heitmann, J.S. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol 22, 74–85 (2021). https://doi.org/10.1038/s41590-020-00808-x
  • Weigelin, B., den Boer, A.T., Wagena, E. et al. Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity. Nat Commun 12, 5217 (2021). https://doi.org/10.1038/s41467-021-25282-3
  • Hinterleitner, C., Strähle, J., Malenke, E. et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun 12, 7005 (2021). https://doi.org/10.1038/s41467-021-27303-7
  • Brendlin, A.S., Peisen, F., Almansour H. et. al. A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma. J Immunother Cancer 9, 11 (2021). 10.1136/jitc-2021-003261 
  • Slaats, J., Dieteren, C.E., Wagena, E. et. al.  Metabolic Screening of Cytotoxic T-cell Effector Function Reveals the Role of CRAC Channels in Regulating Lethal Hit Delivery. Cancer Immunol Res 9, 8 (2021). https://doi.org/10.1158/2326-6066.CIR-20-0741


2022

  • Amaral T, Sinnberg T, Chatziioannou E, Niessner H, Leiter U, Keim U, Forschner A, Dwarkasing J, Tjien-Fooh F, Wever R, Flatz L, Eggermont A, Forchhammer S. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). Eur J Cancer. 2023 Mar;182:155-162. 10.1016/j.ejca.2022.12.021.
  • Zhang Y, Kupferschlaeger J, Lang P, Reischl G, Handgretinger RJ, Fougère C, Dittmann H. 131I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors. J Nucl Med. 2022 Feb;63(2):205-211. 10.2967/jnumed.120.261854.
  • Brendle C, Maier C, Bender B, Schittenhelm J, Paulsen F, Renovanz M, Roder C, Castaneda-Vega S, Tabatabai G, Ernemann U, Fougère C. Impact of 18F-FET PET/MRI on Clinical Management of Brain Tumor Patients. J Nucl Med. 2022 Apr;63(4):522-527. 10.2967/jnumed.121.262051.
  • Aung TN, Shafi S, Wilmott JS, Nourmohammadi S, Vathiotis I, Gavrielatou N, Fernandez A, Yaghoobi V, Sinnberg T, Amaral T, Ikenberg K, Khosrotehrani K, Osman I, Acs B, Bai Y, Martinez-Morilla S, Moutafi M, Thompson JF, Scolyer RA, Rimm DL. Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. EBioMedicine. 2022 Aug;82:104143. 10.1016/j.ebiom.2022.
  • Schmitt J, Schwenck J, Maurer A, Przybille M, Sonanini D, Reischl G, Wehrmüller JE, Quintanilla-Martinez L, Gillies SD, Krueger MA, Schaefer JF, la Fougère C, Handgretinger R, Pichler BJ. Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma. Theranostics. 2022 Jul 18;12(13):5615-5630. 10.7150/thno.56736.
  • Maia A, Schöllhorn A, Schuhmacher J, Gouttefangeas C. CAF-immune cell crosstalk and its impact in immunotherapy. Semin Immunopathol. 2023 Mar;45(2):203-214. 10.1007/s00281-022-00977-x.
  • Slaats J, Wagena E, Smits D, Berends AA, Peters E, Bakker GJ, van Erp M, Weigelin B, Adema GJ, Friedl P. Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors. Cancer Immunol Res. 2022 Dec 2;10(12):1462-1474. 10.1158/2326-6066.CIR-22-0113.
  • Tegeler CM, Bilich T, Maringer Y, Salih HR, Walz JS, Nelde A, Heitmann JS. Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort. Int J Infect Dis. 2022 Jul;120:187-195. 10.1016/j.ijid.2022.04.019.
  • Marcu A, Schlosser A, Keupp A, Trautwein N, Johann P, Wölfl M, Lager J, Monoranu CM, Walz JS, Henkel LM, Krauß J, Ebinger M, Schuhmann M, Thomale UW, Pietsch T, Klinker E, Schlegel PG, Oyen F, Reisner Y, Rammensee HG, Eyrich M. Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors. J Immunother Cancer. 2021 Oct;9(10):e003404. 10.1136/jitc-2021-003404.
  • Lutz MS, Klimovich B, Maurer S, Heitmann JS, Märklin M, Zekri L, Jung G, Salih HR, Hinterleitner C. Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies. J Immunother Cancer. 2022 Feb;10(2):e003655. 10.1136/jitc-2021-003655.
  • Schwarz S, Schmitz J, Löffler MW, Ghosh M, Rammensee HG, Olshvang E, Markel M, Mockel-Tenbrinck N, Dzionek A, Krake S, Arslan B, Kampe KD, Wendt A, Bauer P, Mullins CS, Schlosser A, Linnebacher M. T cells of colorectal cancer patients' stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells. J Immunother Cancer. 2022 Dec;10(12):e005651. 10.1136/jitc-2022-005651.
  • Marcu A, Bichmann L, Kuchenbecker L, Kowalewski DJ, Freudenmann LK, Backert L, Mühlenbruch L, Szolek A, Lübke M, Wagner P, Engler T, Matovina S, Wang J, Hauri-Hohl M, Martin R, Kapolou K, Walz JS, Velz J, Moch H, Regli L, Silginer M, Weller M, Löffler MW, Erhard F, Schlosser A, Kohlbacher O, Stevanović S, Rammensee HG, Neidert MC. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. J Immunother Cancer. 2021 Apr;9(4):e002071. 10.1136/jitc-2020-002071.
  • Marciano S, Ionescu TM, Saw RS, Cheong RY, Kirik D, Maurer A, Pichler BJ, Herfert K. Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks. Proc Natl Acad Sci U S A. 2022 Oct 4;119(40):e2122552119. 10.1073/pnas.2122552119.
  • Montes-Mojarro, IA., Steinhilber, J., Griessinger, C.M. et al. CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL. Leukemia 36, 2050–2063 (2022). https://doi.org/10.1038/s41375-022-01617-x
  • Nies AT, Schaeffeler E, Schwab M. Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation. Pharmacol Ther. 2022 Oct;238:108268. 10.1016/j.pharmthera.2022.108268.
  • Löffler MW, Gori S, Izzo F, Mayer-Mokler A, Ascierto PA, Königsrainer A, Ma YT, Sangro B, Francque S, Vonghia L, Inno A, Avallone A, Ludwig J, Alcoba DD, Flohr C, Aslan K, Mendrzyk R, Schuster H, Borrelli M, Valmori D, Chaumette T, Heidenreich R, Gouttefangeas C, Forlani G, Tagliamonte M, Fusco C, Penta R, Iñarrairaegui M, Gnad-Vogt U, Reinhardt C, Weinschenk T, Accolla RS, Singh-Jasuja H, Rammensee HG, Buonaguro L. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. Clin Cancer Res. 2022 Jun 13;28(12):2555-2566. 10.1158/1078-0432.CCR-21-4424.
  • Löffler MW, Gori S, Izzo F, Mayer-Mokler A, Ascierto PA, Königsrainer A, Ma YT, Sangro B, Francque S, Vonghia L, Inno A, Avallone A, Ludwig J, Alcoba DD, Flohr C, Aslan K, Mendrzyk R, Schuster H, Borrelli M, Valmori D, Chaumette T, Heidenreich R, Gouttefangeas C, Forlani G, Tagliamonte M, Fusco C, Penta R, Iñarrairaegui M, Gnad-Vogt U, Reinhardt C, Weinschenk T, Accolla RS, Singh-Jasuja H, Rammensee HG, Buonaguro L. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. Clin Cancer Res. 2022 Jun 13;28(12):2555-2566. 10.1158/1078-0432.CCR-21-4424.
  • Büttner FA, Winter S, Stühler V, Rausch S, Hennenlotter J, Füssel S, Zastrow S, Meinhardt M, Toma M, Jerónimo C, Henrique R, Miranda-Gonçalves V, Kröger N, Ribback S, Hartmann A, Agaimy A, Stöhr C, Polifka I, Fend F, Scharpf M, Comperat E, Wasinger G, Moch H, Stenzl A, Gerlinger M, Bedke J, Schwab M, Schaeffeler E. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy. Genome Med. 2022 Sep 15;14(1):105. 10.1186/s13073-022-01105-y.
  • Rogal J, Roosz J, Teufel C, Cipriano M, Xu R, Eisler W, Weiss M, Schenke-Layland K, Loskill P. Autologous Human Immunocompetent White Adipose Tissue-on-Chip. Adv Sci (Weinh). 2022 Jun;9(18):e2104451. 10.1002/advs.202104451.
  • Epah J, Gülec I, Winter S, Dörr J, Geisen C, Haecker E, Link D, Schwab M, Seifried E, Schäfer R. From Unit to Dose: A Machine Learning Approach for Precise Prediction of Hemoglobin and Iron Content in Individual Packed Red Blood Cell Units. Adv Sci (Weinh). 2022 Dec;9(36):e2204077. 10.1002/advs.202204077.
  • Pantsar, T., Kaiser, P.D., Kudolo, M. et al. Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors. Nat Commun 13, 569 (2022). https://doi.org/10.1038/s41467-022-28164-4.
  • Urbanczyk M, Zbinden A, Schenke-Layland K. Organ-specific endothelial cell heterogenicity and its impact on regenerative medicine and biomedical engineering applications. Adv Drug Deliv Rev. 2022 Jul;186:114323. 10.1016/j.addr.2022.114323.
  • Weigelin B, Friedl P. T cell-mediated additive cytotoxicity - death by multiple bullets. Trends Cancer. 2022 Dec;8(12):980-987. 10.1016/j.trecan.2022.07.007.
  • Gallage, S., Avila, J.E.B., Ramadori, P. et al. A researcher’s guide to preclinical mouse NASH models. Nat Metab 4, 1632–1649 (2022). https://doi.org/10.1038/s42255-022-00700-y.
  • Wabitsch S, McCallen JD, Kamenyeva O, Ruf B, McVey JC, Kabat J, Walz JS, Rotman Y, Bauer KC, Craig AJ, Pouzolles M, Phadke I, Catania V, Green BL, Fu C, Diggs LP, Heinrich B, Wang XW, Ma C, Greten TF. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol. 2022 Sep;77(3):748-760. 10.1016/j.jhep.2022.03.010.
  • Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann LK, Marcu A, Wolfschmitt EM, Haen S, Gross T, Abdou MT, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng HW, Toma M, Klümper N, Purde MT, Pop OT, Jochum AK, Pascolo S, Joerger M, Früh M, Jochum W, Rammensee HG, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Sci Immunol. 2022 Sep 2;7(75):eabn9644. 10.1126/sciimmunol.abn9644.
  • Maringer Y, Nelde A, Schroeder SM, Schuhmacher J, Hörber S, Peter A, Karbach J, Jäger E, Walz JS. Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Sci Immunol. 2022 Dec 23;7(78):eadd3899. 10.1126/sciimmunol.add3899.
  • Rappold PM, Vuong L, Leibold J, Chakiryan NH, Curry M, Kuo F, Sabio E, Jiang H, Nixon BG, Liu M, Berglund AE, Silagy AW, Mascareno EA, Golkaram M, Marker M, Reising A, Savchenko A, Millholland J, Chen YB, Russo P, Coleman J, Reznik E, Manley BJ, Ostrovnaya I, Makarov V, DiNatale RG, Blum KA, Ma X, Chowell D, Li MO, Solit DB, Lowe SW, Chan TA, Motzer RJ, Voss MH, Hakimi AA. A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2022 Oct 5;12(10):2308-2329. 10.1158/2159-8290.CD-21-0925.
  • Sánchez-Rivera, F.J., Diaz, B.J., Kastenhuber, E.R. et al. Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants. Nat Biotechnol 40, 862–873 (2022). https://doi.org/10.1038/s41587-021-01172-3.
  • Reautschnig, P., Wahn, N., Wettengel, J. et al. CLUSTER guide RNAs enable precise and efficient RNA editing with endogenous ADAR enzymes in vivo. Nat Biotechnol 40, 759–768 (2022). https://doi.org/10.1038/s41587-021-01105-0.
  • Calvanese, V., Capellera-Garcia, S., Ma, F. et al. Mapping human haematopoietic stem cells from haemogenic endothelium to birth. Nature 604, 534–540 (2022). https://doi.org/10.1038/s41586-022-04571-x.
  • Bauer, J., Köhler, N., Maringer, Y. et al. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun 13, 6401 (2022). https://doi.org/10.1038/s41467-022-33746-3            

2023

  • Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023 Feb 4;401(10374):347-356. 10.1016/S0140-6736(22)01841-4.
  • Zekri L, Lutz M, Prakash N, Manz T, Klimovich B, Mueller S, Hoerner S, Hagelstein I, Engel M, Chashchina A, Pfluegler M, Heitmann JS, Jung G, Salih HR. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers. Mol Ther. 2023 Apr 5;31(4):1033-1045. 10.1016/j.ymthe.2023.02.010.
  • Junker D, Becker M, Wagner TR, Kaiser PD, Maier S, Grimm TM, Griesbaum J, Marsall P, Gruber J, Traenkle B, Heinzel C, Pinilla YT, Held J, Fendel R, Kreidenweiss A, Nelde A, Maringer Y, Schroeder S, Walz JS, Althaus K, Uzun G, Mikus M, Bakchoul T, Schenke-Layland K, Bunk S, Haeberle H, Göpel S, Bitzer M, Renk H, Remppis J, Engel C, Franz AR, Harries M, Kessel B, Lange B, Strengert M, Krause G, Zeck A, Rothbauer U, Dulovic A, Schneiderhan-Marra N. Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants. Clin Infect Dis. 2023 Feb 8;76(3):e240-e249. 10.1093/cid/ciac498.
  • Schwenck J, Maurer A, Beziere N, Fiz F, Boschetti F, Geistlich S, Seyfried D, Gunzer M, Reischl G, Wehrmüller J, Ehrlichmann W, Horger M, Gatidis S, Davies G, Vogel W, la Fougere C, Pichler BJ, Thornton C. Antibody-guided Molecular Imaging of Aspergillus Lung Infections in Leukemia Patients. J Nucl Med. 2022 Jul 21:jnumed.121.263251. 10.2967/jnumed.121.263251.
  • Junk SV, Schaeffeler E, Zimmermann M, Möricke A, Beier R, Schütte P, Fedders B, Alten J, Hinze L, Klein N, Kulozik A, Muckenthaler MU, Koehler R, Borkhardt A, Vijayakrishnan J, Ellinghaus D, Forster M, Franke A, Wintering A, Kratz CP, Schrappe M, Schwab M, Houlston RS, Cario G, Stanulla M. Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group. J Exp Clin Cancer Res. 2023 Jan 13;42(1):21. 10.1186/s13046-022-02585-x.
  • Urbanczyk M, Jeyagaran A, Zbinden A, Lu CE, Marzi J, Kuhlburger L, Nahnsen S, Layland SL, Duffy G, Schenke-Layland K. Decorin improves human pancreatic β-cell function and regulates ECM expression in vitro. Matrix Biol. 2023 Jan;115:160-183. 10.1016/j.matbio.2022.12.005.
  • Trautwein NF, Reischl G, Seitz C, Dittmann H, Seith F, Scheuermann S, Feuchtinger T, Dombrowski F, Handgretinger R, Fuchs J, Pichler B, Fougère C, Schwenck J. First-in-Humans PET/MRI of In Vivo GD2 Expression in Osteosarcoma. J Nucl Med. 2023 Feb;64(2):337-338. 10.2967/jnumed.122.264626.
  • Ionescu TM, Amend M, Watabe T, Hatazawa J, Maurer A, Reischl G, Pichler BJ, Wehrl HF, Herfert K. Neurovascular Uncoupling: Multimodal Imaging Delineates the Acute Effects of 3,4-Methylenedioxymethamphetamine. J Nucl Med. 2023 Mar;64(3):466-471. 10.2967/jnumed.122.264391.
  • Feil S, Stowbur D, Schörg BF, Ehrlichmann W, Reischl G, Kneilling M, Pichler BJ, Feil R. Noninvasive Detection of Smooth Muscle Cell-Derived Hot Spots to Study Atherosclerosis by PET/MRI in Mice. Circ Res. 2023 Mar 17;132(6):747-750.  10.1161/CIRCRESAHA.122.322296.
  • Sinnberg T, Lichtensteiger C, Ali OH, Pop OT, Jochum AK, Risch L, Brugger SD, Velic A, Bomze D, Kohler P, Vernazza P, Albrich WC, Kahlert CR, Abdou MT, Wyss N, Hofmeister K, Niessner H, Zinner C, Gilardi M, Tzankov A, Röcken M, Dulovic A, Shambat SM, Ruetalo N, Buehler PK, Scheier TC, Jochum W, Kern L, Henz S, Schneider T, Kuster GM, Lampart M, Siegemund M, Bingisser R, Schindler M, Schneiderhan-Marra N, Kalbacher H, McCoy KD, Spengler W, Brutsche MH, Maček B, Twerenbold R, Penninger JM, Matter MS, Flatz L. Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19. Am J Respir Crit Care Med. 2023 Jan 1;207(1):38-49. 10.1164/rccm.202201-0011OC.
  • Isser S, Maurer A, Reischl G, Schaller M, Gonzalez-Menendez I, Quintanilla-Martinez L, Gawaz M, Pichler BJ, Beziere N. Radiolabeled GPVI-Fc for PET imaging of multiple extracellular matrix fibers: A new look into pulmonary fibrosis progression. J Nucl Med. 2023 Jan 26:jnumed.122.264552. 10.2967/jnumed.122.264552.
  • Perez-Gracia JL, Penel N, Calvo E, Awada A, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF, Castelo-Branco L, Bodoky G, Lolkema MP, Di Nicola M, Casali P, Giuliani R, Pentheroudakis G. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials. Ann Oncol. 2023 Jan;34(1):70-77. 10.1016/j.annonc.2022.09.162.
  • Perez-Gracia JL, Penel N, Calvo E, Awada A, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF, Castelo-Branco L, Bodoky G, Lolkema MP, Di Nicola M, Casali P, Giuliani R, Pentheroudakis G. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials. Ann Oncol. 2023 Jan;34(1):70-77. 10.1016/j.annonc.2022.09.162.
  • Schroeder SM, Nelde A, Walz JS. Viral T-cell epitopes - Identification, characterization and clinical application. Semin Immunol. 2023 Mar;66:101725. 10.1016/j.smim.2023.101725.             
  • Schwenck, J., Sonanini, D., Cotton, J.M. et al. Advances in PET imaging of cancer. Nat Rev Cancer 23, 474–490 (2023). https://doi.org/10.1038/s41568-023-00576-4
  • Naghavian, R., Faigle, W., Oldrati, P. et al. Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma. Nature 617, 807–817 (2023). https://doi.org/10.1038/s41586-023-06081-w
  • Wimmers, F., Burrell, A.R., Feng, Y. et. al. Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth. Cell 186, 21 (2023). https://doi.org/10.1016/j.cell.2023.08.044
  • Flaadt, T., Ladenstein R.L., Ebinger, M. et. al. Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. Journal of Clinical Oncology 41, 17 (2023). https://doi.org/10.1200/JCO.22.01630
  • Sinnberg, T., Lichtensteiger, C., Ali, O.H. et. al. Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19. Am J Respir Crit Care Med 207, 1 (2023). https://doi.org/10.1164/rccm.202201-0011OC
  • D’Artista, L., Moschopoulou A.A., Barozzi I. et. al. MYC determines lineage commitment in KRAS-driven primary liver cancer development. Journal of Hepatology 79, 1 (2023). https://doi.org/10.1016/j.jhep.2023.02.039
  • Heitmann, J.S., Schlenk, R.F., Dörfel, D. et al. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. J Hematol Oncol 16, 96 (2023). https://doi.org/10.1186/s13045-023-01490-w
  • Katiyar, P., Schwenck, J., Frauenfeld, L. et al. Quantification of intratumoural heterogeneity in mice and patients via machine-learning models trained on PET–MRI data. Nat. Biomed. Eng 7, 1014–1027 (2023). https://doi.org/10.1038/s41551-023-01047-9
  • Bucher, P., Feucht, J. LINKing signaling domains to enhance CAR T cells. Nat Cancer 4, 447–449 (2023). https://doi.org/10.1038/s43018-023-00538-7
  • Váraljai, R., Zimmer, L., Al-Matary, Y. et al. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer 4, 1292–1308 (2023). https://doi.org/10.1038/s43018-023-00610-2
  • Ghasemi, A., Martinez-Usatorre, A., Li, L. et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Nat Cancer (2023). https://doi.org/10.1038/s43018-023-00668-y
  • Odak, A., Yuan, H., Feucht, J. et. al. Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering. Blood 141, 22 (2023). https://doi.org/10.1182/blood.2022018924
  • Bamezai, S., Pulikkottil, A.J., Yadav, T. et. al. A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Blood 142, 1 (2023). 10.1182/blood.2022018651 
  • Schmitt, A., Grimm, M., Kreienkamp, N. et al. BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis. Blood 142, 13 (2023). https://doi.org/10.1182/blood.2022019274
  • Heitmann, J.S., Tandler, C., Marconato, M. et al. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency. Nat Commun 14, 5032 (2023). https://doi.org/10.1038/s41467-023-40758-0
  • Rousseau, V., Einig, E., Jin, C. et al. Trim33 masks a non-transcriptional function of E2f4 in replication fork progression. Nat Commun 14, 5143 (2023). https://doi.org/10.1038/s41467-023-40847-0
  • Goyal, A., Bauer, J., Hey, J. et al. DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts. Nat Commun 14, 6731 (2023). https://doi.org/10.1038/s41467-023-42417-w
  • Hoenisch Gravel, N., Nelde, A., Bauer, J. et al. TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification. Nat Commun 14, 7472 (2023). https://doi.org/10.1038/s41467-023-42692-7
  • Wang, J.Z., Patil, V., Liu, J. et al. Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas. Acta Neuropathol 146, 145–162 (2023). https://doi.org/10.1007/s00401-023-02571-3
  • Santos Amaral, T.M., Pop, O.T., Chatziioannou, E. et. al. EGFR expression and relapse in patients with melanoma receiving adjuvant PD-1-based immunotherapy. Journal of Clinical Oncology 41, 16 (2023). https://doi.org/10.1200/JCO.2023.41.16_suppl.e21566
  • Anderle, N., Schäfer-Ruoff, F., Staebler, A. et al. Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment. J Exp Clin Cancer Res 42, 210 (2023). https://doi.org/10.1186/s13046-023-02782-2
  • Schwenck, J., Sonanini, D., Seyfried, D. et. al. In vivo imaging of CD8+ T cells in metastatic cancer patients: first clinical experience with simultaneous [89Zr]Zr-Df-IAB22M2C PET/MRI. Theranostics 13, 8 (2023). 10.7150/thno.79976
  • Gaißler, A., Bochem, J., Spreuer, J. et. al. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. J Immunother Cancer 11, 6 (2023). 10.1136/jitc-2023-006802 
  • Knopf, P., Stowbur, D., Hoffmann, S.H.L. et al. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. Mol Cancer 22, 207 (2023). https://doi.org/10.1186/s12943-023-01900-0
  • Becker, L., Lu, C.E., Montes-Mojarro, I.A. et. al. Raman microspectroscopy identifies fibrotic tissues in collagen-related disorders via deconvoluted collagen type I spectra. Acta Biomaterialia 162, 278-291 (2023). https://doi.org/10.1016/j.actbio.2023.03.016

2024

  • Leibold, J., Tsanov, K.M., Amor, C. et al. Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease. Nat Cancer  (2024). https://doi.org/10.1038/s43018-023-00686-w
  • Sleeboom, Jelle J.F., Van Tienderen, Gilles S., Schenke-Layland, Katja et al. The extracellular matrix as hallmark of cancer and metastasis: From biomechanics to therapeutic targets. Science Translational Medicine 16, 728 (2024). https://doi.org/10.1126/scitranslmed.adg3840
  • Ghasemi, A., Martinez-Usatorre, A., Li, L. et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Nat Cancer 5, 240–261 (2024). https://doi.org/10.1038/s43018-023-00668-y
  • Hartmann, A., Passauer, J., Hartmann, J. et al. Grundprinzipien der künstlichen Intelligenz in der Dermatologie erklärt am Beispiel des Melanoms: Basic principles of artificial intelligence in dermatology explained using melanoma. J Dtsch Dermatol Ges. 22, 3 (2024). https://doi.org/10.1111/ddg.15322_g
  • Singvogel, K., Schittek, B. Dormancy of cutaneous melanoma. Cancer Cell Int 24, 88 (2024). https://doi.org/10.1186/s12935-024-03278-5
  • Fend, F., van den Brand, M., Groenen, P.J. et al. Diagnostic and prognostic molecular pathology of lymphoid malignancies. Virchows Arch 484, 195–214 (2024). https://doi.org/10.1007/s00428-023-03644-0
  • Serafin, R.A.M., Gehringer, M., Borsari, C. et al. Targeted Covalent Inhibitors in Drug Discovery, Chemical Biology and Beyond. Pharmaceuticals 17, 2 (2024). https://doi.org/10.3390/ph17020206
  • Fortuna, A., Amaral, T. Multidisciplinary approach and treatment of acral and mucosal melanoma. Front Oncol 14 (2024). https://doi.org/10.3389/fonc.2024.1340408 
  • Duran, I., Pombo, J., Sun, B. et al. Detection of senescence using machine learning algorithms based on nuclear features. Nat Commun 15, 1041 (2024). https://doi.org/10.1038/s41467-024-45421-w
  • Jansen, R.A., Mainardi, S., Dias, M.H. et al. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers. Proc Natl Acad Sci USA 121, 9 (2024). https://doi.org/10.1073/pnas.2319492121
  • Leibold, J., Tsanov, K.M., Amor, C. et al. Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease. Nat Cancer 5, 315–329 (2024). https://doi.org/10.1038/s43018-023-00686-w
  • Hartmann, T., Passauer J., Hartmann, J. et al. Basic principles of artificial intelligence in dermatology explained using melanoma. J Dtsch Dermatol Ges. 22, 3 (2024). https://doi.org/10.1111/ddg.15322
  • Hoyt, K.W., Urul, A.D., Ogboo, B.C. et al. Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors. J. Med. Chem. 67, 1 (2024). https://doi.org/10.1021/acs.jmedchem.3c01502
  • Ribeiro, E.M., Secker, K., Nitulescu, A. et al. PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity. J Immunother Cancer 21, 1 (2024). https://doi.org/10.1136/jitc-2023-007829
  • Le Teuff, G., Cozic, N., Boyer, JC. et al. Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis. Br J Cancer 130, 808–818 (2024). https://doi.org/10.1038/s41416-023-02517-2
  • Walter, B., Hirsch, S., Kuhlburger, L. et al. Functionally-instructed modifiers of response to ATR inhibition in experimental glioma. J Exp Clin Cancer Res 43, 77 (2024). https://doi.org/10.1186/s13046-024-02995-z
  • Wittlinger, F., Ogboo, B.C., Shevchenko, E. et al. Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Commun Chem 7, 38 (2024). https://doi.org/10.1038/s42004-024-01108-3
  • Herold, N., Bruhns, M., Babaei, S. et al. High-dimensional in situ proteomics imaging to assess γδ T cells in spatial biology. Journal of Leukocyte Biology 115, 1 (2024). https://doi.org/10.1093/jleuko/qiad167
  • Paranawithana, N.N., Chiaffarelli, R., Kretschmer, J. et al. Enhancing r1 Relaxivity in GdDOTA-Monoamide Complexes through Polar Group-Mediated Ordering of Second-Sphere Water Molecules Inorg. Chem. 63, 9 (2024). https://doi.org/10.1021/acs.inorgchem.3c03639
  • Lutz, M., Wang, K., Jung, G. et al. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer. Front Immunol. 15 (2024). https://doi.org/10.3389/fimmu.2024.1343929 
  • Wessels Perelo, L., Gabernet, G., Straub, D. et al. How tool combinations in different pipeline versions affect the outcome in RNA-seq analysis. NAR Genom Bioinform. 6, 1 (2024). https://doi.org/10.1093/nargab/lqae020
  • Vogel, J., Sekler, J., Gückel, B. et al. How [18F]FDG-PET/CT Affects the Management of Patients with Differentiated Thyroid Carcinoma in Clinical Routines. Cancers (Basel) 16, 3 (2024). https://doi.org/10.3390/cancers16030588
  • Meraz-Torres, F., Niessner, H., Plöger, S. et al. Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy. J Exp Clin Cancer Res 43, 30 (2024). https://doi.org/10.1186/s13046-023-02941-5
  • Trautwein, N.F., Schwenck, J., Seitz, C. et al. A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [64Cu]Cu-NOTA-ch14.18/CHO Theranostics 14, 3 (2024). 10.7150/thno.92481 
  • Bowden, G.D., Stotz, S., Dunkel, G. et al. [18F] p FBC, a Covalent CLIP-Tag Radiotracer for Detection of Viral Reporter Gene Transfer in the Murine Brain. Bioconjug Chem. 35, 2 (2024). https://doi.org/10.1021/acs.bioconjchem.3c00551
  • Zekri, L., Hagelstein, I., Märklin, M. et al. Immunocytokines with target cell–restricted IL-15 activity for treatment of B cell malignancies. Science Translational Medicine 16, 737 (2024). 10.1126/scitranslmed.adh1988 
  • El-Ayoubi, A., Arakelyan, A., Klawitter, M. et al. Development of an optimized, non-stem cell line for intranasal delivery of therapeutic cargo to the central nervous system. Molecular Oncology 18, 3 (2024). https://doi.org/10.1002/1878-0261.13569
  • Scheurer, J., Sauer, B., Focken, J. et al. Histological and functional characterization of 3D human skin models mimicking the inflammatory skin diseases psoriasis and atopic dermatitis. Disease Models & Mechanisms 17, 1 (2024). https://doi.org/10.1242/dmm.050541
  • Menzel, F., Cotton, J., Ziegler, T. et al. Open-source flow setup for rapid and efficient [18F]fluoride drying for automation of PET tracer syntheses. J Labelled Comp Radiopharm. 67, 2 (2024). https://doi.org/10.1002/jlcr.4080
  • Zwirner, S., Zender, L., Klotz, S. et al. First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell 187, 1-19 (2024). https://doi.org/10.1016/j.cell.2024.02.023
  • Maier, C., Klose, C., Seitz, C.M. et al. Influence of ATLG Serum Levels on CD3/CD19-depleted Hematopoietic Grafts and on Immune Recovery in Pediatric Haplo-HSCT. Blood Adv. 8, 3 (2024). https://doi.org/10.1182/bloodadvances.2023011016
  • Eichholz, T., Heubach, F., Arendt, AM. et al. Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3. Cancer Immunol Immunother 73, 19 (2024). https://doi.org/10.1007/s00262-023-03587-0
  • Baumgartner, F., Bamopoulos, S., Faletti, L. et al. Activation of gp130 signaling in T cells drives TH17-mediated multi-organ autoimmunity. Science Signaling 17, 824 (2024). 10.1126/scisignal.adc9662 
  • Amaral, T., Nanz, L., Stadler, R. et al. Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB. Eur J Cancer 201 (2024). https://doi.org/10.1016/j.ejca.2024.113912
  • Peisen, F., Gerken, A., Dahm, I. et al. Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy. Plos One 19, 1 (2024). 10.1371/journal.pone.0296253 
  • Reiner, C.P., Pfannenberg, C., Gückel, B. et al. Preoperative Assessment of Medication-Related Osteonecrosis of the Jaw Using [18F]fluoride Positron Emission Tomography (PET)/CT and [18F]fluorodeoxyglucose PET/MRI in Correlation with Histomorphometry and Micro-CT-A Prospective Comparative Study. Diagnostics (Basel) 14, 4 (2024). https://doi.org/10.3390/diagnostics14040428
  • Trautwein, N.F., Hinterleitner, C., Kiefer, L.S. et al. Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study. Clin Nucl Med 49, 3 (2024). 10.1097/RLU.0000000000005006 
  • Yang, Q., Deng, S., Preibsch, H. et al. Image-guided metabolomics and transcriptomics reveal tumour heterogeneity in luminal A and B human breast cancer beyond glucose tracer uptake. Clin Transl Med. 14, 2 (2024). https://doi.org/10.1002/ctm2.1550
  • Schmidt, F., Allen, M.S., Ladebeck, R. et al. Evaluation of the MRI compatibility of PET detectors modules for organ-specific inserts in a 3T and 7T MRI scanner. Medical Physics 51, 2 (2024). https://doi.org/10.1002/mp.16923